RE:RE:Not surprisingI know everyone is distressed by the news on TH-1902 but the legacy drugs continue to sell well and if that continues and they get the one filing done, TH will actually be getting more money from Marathon in June 2023 to complete the financing of the convert redemption. The agreement for that to happen is already in place.
So far I have seen analyst reports from Jones, Cantor and Research Capital. All have maintained their Buy ratings and target prices, even Jones where a significant part of the target price was made up from TH-1902 future values. Jones was the only analyst who gave any value for TH-1902. These reports also indicate the issue was more efficacy being too mild and not really a side-effect problem. Apparently, a 100mg dose given almost weekly is being considered.
TH-1902 is not dead but it is delayed. That is unfortunate but not an existential crisis. The stock's sell-off is overdone given the value of the legacy drugs. Trading volume so faris lighter than I expected given the news, so that is promising. Sellng at these prices certainly seems like a sub-optimal reaction.
jeffm34 wrote: TH isn't even that anymore. Marathon Asset Management owns the legacy drugs when TH defaults
Momo25 wrote:
tH is now clearly a company of legacy drug, not more. No one will put a penny on the Nash program neither.